Fruits of mind after the 2nd International Conference on Metabolomics and Health
Published in Chemistry and Protocols & Methods
The 2nd International Conference on Metabolomics and Health was held in Shanghai from April 27–30, 2026. The organizers—Professor Huiru Tang, Professor Yulan Wang, and Professor Jia Li—graciously provided BMC Medicine with the opportunity to attend the conference as a visitor.
In summary, the conference featured cutting-edge presentations on recent advances and insights across several domains:
-
Advances in Metabolomics Technologies
-
Metabolomics in Pathophysiology
-
Host–Microbiota Symbiotic Interactions
-
Exposome and Health
The conference assembled experts, students, and journalists from around the world. The majority of presentations were delivered in English. This experience afforded me a broad understanding of newly developed mass spectrometry–based techniques for omics studies at the single-cell scale and beyond, the application of metabolomics and microbiota characterization in disease diagnosis and precision medicine, and the correlation between the exposome and disease development across different stages of the human lifespan. I greatly appreciated the diversity of topics addressed.
Additionally, at the conference also features "Women in Science" session, during which Prof. Yulan Wang, Jia Li, Elaine Holmes, Sastia Prama Purti (female) , and Prof. Hongwei Zhou, Zongwei Cai (male) voiced their opinions on how to help women develop their careers in science. They shared stories about the support they received from other women throughout their careers. They encourage all to bravely make requests for promotions, salary increases, and co-authorship. The dilemma mentioned for women is the overlapping timelines between career development and family responsibilities. At the end of the session, they envision a society in which all collaborate to foster a more friendly environment, helping women's development, and where men and women share equal responsibilities for the care of the elderly and offspring.
Below, I highlight two compelling talks.
I was pleased to meet Professor Zhigang Liu in person, as he has served as an editorial board member for the Gastroenterology section of BMC Medicine. His research interests span gut microbiome–host interactions, novel therapeutic interve6ntions, and epidemiological data analysis. His talk addressed the role of metabolites as active regulators of gut inflammation and their implications in the pathogenesis of inflammatory bowel disease (IBD), integrating findings from experimental models and human cohorts. His results provided additional evidence for a unifying model in which host–microbiota co-metabolism constitutes a regulatory axis driving intestinal inflammation.
Another noteworthy presentation was delivered by Professor Huiru Tang, a well-recognized figure in metabolomics and systems biology. I attended two of his talks—one during the pre-conference technical training sessions and another during the main conference. Professor Tang's research group has made substantial efforts to develop quantitative techniques for trace metabolomics in complex mixtures. They have developed novel probes to elucidate unknown metabolite structures, thereby providing metabolomic phenotypic insights into major diseases using advanced NMR- and MS-based methodologies. A recent publication from his group proposed a metabolome-derived score that predicts metabolic dysfunction-associated steatohepatitis (MASH) and liver disease mortality.
Given the strong implications of metabolomics and the gut microbiota in multiple diseases, a growing number of studies have focused on modeling microbiome or metabolomic data to predict disease risk, diagnosis, prognosis, and treatment response. Some have concerns over the accuracy and generalizability of such models given the heterogeneity of populations and on patient level. This raises a critical question: What are the current challenges of modeling metabolomics and gut microbiota statistics for disease risk prediction and precision medicine? Please share your comments below.
Written by Yonghong Ding, an editor of BMC Medicine
I am a journal editor at BMC Medicine responsible contents from Gastroenterology and Oncology sections.
Follow the Topic
-
BMC Medicine
This journal publishes outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities.
Related Collections
With Collections, you can get published faster and increase your visibility.
Cardiac immunity and inflammation
BMC Medicine invites submissions to a new Collection focused on the interplay between cardiac immunity and inflammation. We welcome original research, translational studies, and comprehensive reviews that elucidate the underlying mechanisms, clinical consequences, and therapeutic opportunities arising from immune-cardiac interactions. By highlighting the importance of this link, we aim to foster collaboration and advance our understanding of how to improve patient outcomes in heart disease.
The intersection of immunity and cardiovascular biology represents a transformative frontier in modern medicine. Recent studies have highlighted the role of immune responses in various heart conditions, including myocarditis, cardiac xenotransplantation, and heart failure. Inflammation is increasingly recognized as a contributing factor to the pathogenesis and residual risk factor of cardiovascular diseases. This Collection aims to explore the mechanisms by which immune responses influence cardiac function, the role of clonal hematopoiesis and heart disease, and the implications of such interactions for cardiac outcomes.
Understanding cardiac immunity and inflammation is crucial for developing more targeted therapies and accurate CVD risk prediction. Past advances provided insights into the inflammatory processes involving cardiovascular conditions, leading to innovative approaches for diagnosis and treatment. For instance, the identification of biomarkers such as C-reactive protein enhances our ability to assess inflammation in patients with cardiovascular disease. Furthermore, the intersection of cardio-oncology has opened new avenues for research into how cancer therapies influence cardiac immune responses, emphasizing the need for a multidisciplinary approach to patient management.
Continued research in this field holds promise for unveiling drug discovery targets and strategies to mitigate inflammation-related cardiac damage. As we deepen our understanding of the immune mechanisms at play, we may see the development of more clinically relevant models of human disease and precision medicine approaches tailored to individual patients. The integration of this knowledge with advancements in technology, such as biomarker discovery and imaging techniques, could revolutionize the way we approach cardiac care.
Topics of interest include (but are not limited to):
- Role of immunity in cardiovascular biomedicine
- Systemic and cardiac-specific inflammatory pathways
- Residual inflammatory risk, e.g. “SMuRF-less but inflamed”
- Cross-organ communication and immune crosstalk
- Structural and functional cardiac remodeling driven by inflammation
- Novel biomarkers and prediction models
- Clonal hematopoiesis
- Cardio-oncology & therapy-induced immune modulation
- The role of immunity in cardiac xenotransplantation including partial heart transplantation
- Exposome/environmental exposures
- Epigenetic regulation of cardiac immunity and inflammation
- Immune memory and trained immunity in cardiovascular contexts
- Multi-omics integration (epigenomics, transcriptomics, proteomics) in cardiac disease
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
This Collection supports and amplifies research related to SDG 3 (Good Health and Well Being).
Publishing Model: Open Access
Deadline: Feb 01, 2027
Organoids: connecting molecular insights and clinical practice
BMC Medicine is calling for submissions to our new Collection exploring the use of organoids in connecting molecular insights with clinical practice. We welcome research that investigates their applications in molecular medicine, precision medicine, regenerative medicine, and the understanding of inter-organ crosstalk. Through this Collection, we aim to showcase the transformative potential of organoids in advancing biomedical research and improving patient outcomes.
Organoids, three-dimensional structures derived from stem cells, mimic the architecture and function of real organs, providing a groundbreaking platform for studying human biology and disease. These miniature organs have emerged as powerful tools in biomedical research, enabling scientists to explore complex biological processes, drug responses, and disease mechanisms in a controlled environment. By bridging the gap between traditional 2D cell cultures and in vivo models, organoids offer unprecedented opportunities to investigate cellular interactions, tissue development, and organ-specific functions.
Advancements in organoid technology have been instrumental in enhancing our understanding of various diseases, including but not limited to cancer, neurodegenerative disorders, and infectious diseases. Their capacity for personalized medicine, where patient-specific organoids are used to test drug efficacy, represents a significant leap towards tailored therapies. Furthermore, organoids facilitate the study of inter-organ crosstalk and molecular communication, revealing insights into systemic responses and disease progression that were previously difficult to achieve.
As research in this field continues to grow, we can anticipate innovative applications of organoids in regenerative medicine, the development of novel therapeutic strategies, and the potential for real-time monitoring of disease progression and treatment responses. The integration of multi-organoid systems may also pave the way for more complex models that better reflect human physiology, ultimately transforming clinical practice.
Topics of interest include but are not limited to:
- Organoids in development biology and disease modeling
- Insights into disease mechanisms through organoid models
- Applications of organoids in precision medicine
- Advances in 3D cell culture technologies
- Inter-organ crosstalk and molecular communication
- Organoids in regenerative medicine
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Nov 17, 2026
